HTRA1 Antibody, FITC Conjugated is a fluorescently labeled immunoglobulin designed to bind specifically to HTRA1. FITC conjugation allows visualization under fluorescence microscopy or flow cytometry, making it indispensable for:
Immunofluorescence (IF/ICC)
Western blotting (WB)
Flow cytometry (FC)
Enzyme-linked immunosorbent assays (ELISA)
The conjugation process involves covalent attachment of FITC to the antibody, preserving its antigen-binding specificity while enabling fluorescence-based detection .
HTRA1 interacts with amyloidogenic proteins like α-synuclein and TDP-43. FITC-conjugated antibodies have been used to:
Track HTRA1’s intracellular localization during α-synuclein disaggregation .
Monitor HTRA1 levels in cerebrospinal fluid (CSF) of multiple sclerosis patients, where elevated HTRA1 correlates with disease progression .
In AMD models, FITC-labeled antibodies quantified HTRA1 inhibition efficacy in vitreous humor, showing dose-dependent activity suppression .
In membranous nephropathy (MN), anti-HTRA1 antibodies (IgG4 subclass) were detected using immunoblotting and ELISA, with FITC conjugates aiding in immune deposit localization .
Knockout Validation: Antibodies like ab274322 (non-conjugated) demonstrate specificity via knockout cell lines, with no cross-reactivity in HTRA1-deficient HAP1 cells .
Proteomic Profiling: HTRA1-directed activity-based probes (ABPs) combined with FITC-conjugated antibodies identified substrates like Dickkopf-related protein 3 in ocular tissues .
Storage: Most FITC-conjugated antibodies require storage at -20°C with avoidance of freeze-thaw cycles .
Dilution Ranges:
Biomarker Potential: HTRA1 in CSF serves as a diagnostic marker for multiple sclerosis (AUC = 0.903 in ROC analysis) .
Therapeutic Targeting: Anti-HtrA1 Fab inhibitors, validated using FITC-based probes, show promise in preclinical AMD models .